ClinicalTrials.gg
RecruitingNCT04836507Updated Jul 1, 2026

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

A Phase 1/2 interventional study of CRC01 and Fludarabine in Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL), sponsored by Curocell Inc.. Recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Curocell Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies in Lymphoma, Large B-Cell, Diffuse with a site in Korea, Republic of — 15 open to participants now, 34 under way, 11 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Korea, Republic of.

Planned enrollment
42nd of 87
91 · median 90
Started
2021
with 7 others
Phase 1/2
16 of 97
6 open now
Primary completion
2030-08
later than 30 of 33 live
Registered
67th of 97
by date

Among the 97 studies in Lymphoma, Large B-Cell, Diffuse with a site in Korea, Republic of, this one is the 42nd largest by planned enrollment of the 87 interventional ones that give a count, is one of 8 that started in 2021, is one of 16 in phase 1/2, reaches primary completion later than 30 of the 33 other live ones, and was the 67th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

15 of the 97 studies in Lymphoma, Large B-Cell, Diffuse with a site in Korea, Republic of are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Lymphoma, Large B-Cell, Diffuse with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.

03

Conditions studied

  • Relapsed Large B-cell Lymphoma
  • Refractory Large B-cell Lymphoma
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
  • High-grade B-cell Lymphoma
  • Transformed Follicular Lymphoma (TFL)
  • ALL (Acute B-Lymphoblastic Leukemia)

Keywords

  • CRC01
  • anti-CD19 CAR-T
  • CAR-T
  • CAR T cells
  • Chimeric antigen receptor
  • PD-1 knock down
  • TIGIT knock down
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Cohort A:

Inclusion Criteria:

  1. ≥ 19 years of age and provided written
  2. confirmed following large B-cell lymphomas according to the World Health Organization classification 2017

    • Diffuse large B-cell lymphoma, not otherwise specified Including Large cell transformation from follicular lymphoma (Transformed follicular lymphoma)
    • High-grade B-cell lymphoma, not otherwise specified
    • High-grade B-cell lymphoma with double-hit/triple-hit
    • Primary mediastinal large B cell lymphoma
  3. disease after ≥ two including rituximab, anthracycline and either having failed Hematopoietic stem cell transplantation (ASCT) or being ineligible for or not consenting to ASCT.
  4. At least one (Long diameter ≥ 1.5cm)
  5. (ECOG) performance status 0 or 1
  6. Adequate renal and hepatic functions based on the laboratory test results

    • Total ≤ 2.0mg/dL with the exception of patients with Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome may be included if their total bilirubin is ≤ 3 X and direct bilirubin ≤ 1.5 X ULN.
    • (AST) and Alanine transaminase (ALT) ≤ 3 X Upper Limit of Normal (ULN) for age with exception of liver ; patients with liver metastasis may be included if their AST and ALT are ≤ 5 X ULN.
    • Serum creatinine ≤ 1.5 X ULN
    • Estimated (eGFR) ≥ 60mL/min/1.73m2
  7. Adequate hematologic function without transfusions within 2 weeks prior to screening for the study defined as followings:

    • > 8.0g/㎗
    • (ANC) > 1,000/㎕
    • Absolute Lymphocyte Count (ALC) ≥ 300/㎕
    • ≥ 50,000/㎕
  8. Must have a minimum level of pulmonary reserve defined as;

    • ≤ Grade 1 dyspnea per (CTCAE) v5.0
    • pulse oxygenation > 91% on room air
  9. Hemodynamically stable, without pericardial effusion and Left Ventricle (LVEF) ≥ 50% confirmed by Echocardiogram () or Multigated Radionuclide Angiography (MUGA)
  10. Must have an apheresis product of non-mobilized cells accepted for manufacturing
  11. ≥ 12 weeks
  12. Women of and all male participants must agree to use highly effective methods of for at least 12 months following CRC01 infusion and until CRC01 are no longer present by PCR on two consecutive tests

Exclusion Criteria:

  1. Patients with the following medical history

    • Previous or concurrent with the following exceptions:

      • Adequately treated basal cell or squamous cell carcinoma without evidence of recurrence for at least 3 years prior to the study
      • In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study
      • A primary malignancy which has been completely resected and in complete remission for ≥ 5 years
    • Unstable angina and/or myocardial infarction within 12 months prior to screening
    • Thromboembolic events, pulmonary embolism or bleeding diatheses within 6 months prior to screening
    • Hypoxemia, significant pleural effusion or significant EKG findings within 6 months prior to the screening
  2. Patients with the following concurrent disease at screening:

    • Central Nervous System (CNS) involvement by malignancy by MRI at screening
    • Active infection with (HBsAg positive. But, in case of HBcAb IgG positive, the patient can be enrolled in this study if he/she takes prophylactic anti-viral agent.)
    • Active infection with (HCV RNA positive)
    • (HIV) positive
    • Active neurological auto-immune or inflammatory disorder (e.g. Guillain Barre Syndrome, Amyotrophic Lateral Sclerosis)
    • Ventricular tachycardia and atrial fibrillation with rapid ventricular response not controlled with medical treatment within 3 months prior to screening
  3. Rapidly progressing the disease as per investigator's discretion
  4. Had major surgery requiring general anesthesia or mechanical ventilation within 4 weeks prior to screening (For video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery can be applied with within 2 weeks prior to screening.)
  5. Severe infection requiring anti-bacterial, anti-fungal or anti-viral medication or uncontrolled active infection
  6. The following treatment history is excluded:

    • Prior treatment with any prior anti-CD19/anti-CD3 therapy or any other anti-CD19 therapy
    • Prior treatment with any adoptive T cell therapy
    • Treatment with any prior gene therapy product
    • Prior allogeneic HSCT
    • Patients on oral anticoagulation therapy
  7. Eligible for and consenting to ASCT
  8. Use of medicinal product/device within 4 weeks prior to screening
  9. Pregnant or lactating women
  10. reaction to the of CRC01 cell product
  11. The following treatments are excluded:

    • Anti-neoplastic therapies including chemotherapy, biologic agents, retinoid therapy, radiotherapy, immune therapy, hormonal therapy, etc. other than lymphodepleting chemotherapy within 2 weeks of leukapheresis and within 2 weeks of CRC01 infusion
    • : therapeutic doses of steroids must be stopped > 7 days prior to leukapheresis and > 5 days prior to CRC01 infusion. However, the following physiological replacement doses of steroids are allowed: \< 6 mg/m2/day hydrocortisone or equivalent
    • : any immunosuppressive medication must be stopped > 4 weeks prior to leukapheresis and > 4 weeks prior to CRC01 infusion
    • Antibody use including anti-CD20 therapy within 4 weeks prior to CRC01 infusion
    • CNS disease prophylaxis must be stopped > 1 week prior to CRC01 infusion (e.g. intrathecal methotrexate)

Cohort B :

Inclusion Criteria :

  1. ≥ 19 years of age and provided written informed consent to voluntarily participate in this trial
  2. Relapsed or refractory B-cell lymphoblastic leukemia with one of the following:

    • Primary refractory: Newly diagnosed and refractory to 2 or more cycles of standard chemotherapy
    • Relapsed within 12 months of the first complete remission
    • Chemorefractory: Refractory to 1 cycle of chemotherapy conducted after relapse
    • Relapsed after or refractory to two or more lines of chemotherapy
    • Relapsed or refractory 100 days after allogeneic HSCT
  3. (within 4 weeks prior to screening) Blast of > 5% identified in the BM
  4. (within 4 weeks prior to screening) BM or peripheral blood blast confirmed CD19-positive.

    Specifically, those with prior treatment with any other anti-CD19 therapy must be confirmed to show CD19 ≥ 90%.

  5. Philadelphia chromosome positive with one of the following:

    • Unable to take tyrosine kinase inhibitors (TKIs) due to side effects
    • Relapsed or refractory despite treatment with two or more TKIs
  6. ECOG performance status of 0-1
  7. Confirmed adequate hematologic function defined as follows:

    • Absolute neutrophil count (ANC) ≥ 500/μL. However, exceptions are made in cases where the Investigator determines that cytopenia is related to the leukemia and may be recovered with leukemia treatment.
    • Platelet count ≥ 50,000/μL. However, exceptions are made in cases where the Investigator determines that cytopenia is related to the leukemia and may be recovered with leukemia treatment.
    • Absolute lymphocyte count ≥ 200/μL
  8. Adequate renal and hepatic functions confirmed based on the laboratory test results:

    • Total Bilirubin ≤ 2.0 mg/dL (for patients with Gilbert-Meulengracht syndrome, total bilirubin ≤ 3 × ULN and direct bilirubin ≤ 1.5 × ULN)
    • AST and ALT ≤ 3 × ULN
    • Serum creatinine ≤ 1.5 × ULN or eGFR* ≥ 45 mL/min/1.73 m2 *MDRD-GFR (mL/min/1.73 m2) = 186 × (serum creatinine)-1.154 × (age)-0.203 (× 0.742 for females)
  9. Confirmed to have a minimum level of pulmonary reserve according to the following criteria:

    • ≤ Grade 1 dyspnea per CTCAE v5.0
    • Pulse oxygenation > 91% on room air
  10. Hemodynamically stable, without pericardial effusion, and LVEF ≥ 50% confirmed by ECHO or MUGA scan at Screening
  11. Capable of obtaining through leukapheresis non-mobilized cells adequate for CRC01 manufacturing
  12. Life expectancy of ≥ 12 weeks
  13. Consented to comply with the site visit and test schedules for Primary Follow-up and Secondary Follow-up in accordance with the Protocol for the duration of the Study
  14. WOCBP or male subjects who are willing to use appropriate contraceptive methods* for at least 12 months following CRC01 treatment and until CRC01 is no longer detected through two consecutive PCR tests * Hormonal contraceptives, placement of intrauterine system, double barrier method (simultaneous use of contraceptive vaginal diaphragm or cervical cap and male condom, along with spermicide), sterilization (vasectomy, bilateral tubal ligation), etc.

Exclusion Criteria:

Patients in Cohort B may not participate in this trial if any of the following criteria apply.

  1. Patients with the following medication or treatment history:

    ① Donor lymphocyte infusion (DLI) within 4 weeks

    • Graft-versus-host-disease () treatment within four weeks (In case of maintaining medication for post-treatment prophylaxis, the decision on the subject's participation in the clinical trial may be made after contacting and consulting with the Sponsor's Medical Monitor.)

      • Central nervous system (CNS) radiotherapy or intracerebrospinal antineoplastic therapy within eight weeks (However, intrathecal therapy for prophylaxis purposes is an exception) ④ Systemic salvage chemotherapy that includes TKI and blinatumomab for treatment of Philadelphia positive ALL within one week prior to Screening or five half-lives of the administered drug (whichever is shorter)

        • Any prior anti-CD19 treatment (with the exception of blinatumomab) ⑥ History of neurological toxicity ≥ Grade 4 or cytokine release syndrome (CRS) ≥ Grade 4 per CTCAE during prior anti-CD19 treatment
  2. Patients with the following CNS abnormality:

    ① CNS-3 disease, defined by WBC ≥ 5/μL in CSF and confirmed presence of lymphoblast, with or without neurological symptoms

    ② CNS-3 disease, defined by WBC \< 5/μL in CSF and confirmed presence of lymphoblast, with neurological symptoms (cases of CNS-1 disease without evidence of leukemia involvement in CSF and CNS-2 disease without neurological symptoms may be enrolled)

    ③ Current or prior history of CNS disorder, such as epilepsy/seizure, cerebrovascular ischemia/bleeding, dementia, cerebellar disorder, disease with CNS invasion, posterior reversible encephalopathy syndrome (PRES) or cerebral edema

  3. Burkitt's lymphoma/leukemia per WHO Classification or chronic myelogenous leukemia lymphoid blast crisis
  4. Primary immunodeficiency
  5. Hereditary diseases (e.g., Fanconi anemia, Kostmann syndrome, and Shwachman-Diamond syndrome) or other bone marrow failure syndromes

2. Common Exclusion Criteria

Subjects in Phase 1 study and Phase 2 study may not participate in this trial if any of the following criteria apply.

  1. Patients with the following medical history:

    • History of malignancy with the following exceptions:

      • Basal cell or squamous cell skin cancer treated without relapse for at least three years prior to Screening
      • In-situ carcinoma of the cervix or breast treated without relapse for at least 3 years prior to Screening
      • Superficial bladder cancer treated without relapse for at least 3 years prior to Screening
      • A primary malignancy which has been completely resected and in complete remission for ≥ 5 years

        • Unstable angina and/or myocardial infarction within 12 months prior to Screening ③ Thromboembolic events, pulmonary embolism or bleeding diatheses within 6 months prior to Screening

          • Hypoxemia, pleural effusion or clinically significant ECG findings within 6 months prior to Screening
  2. Patients with the following concurrent disease at Screening:

    • Central nervous system (CNS) involvement by malignancy by magnetic resonance imaging (MRI) at Screening. However, for Cohort B, subjects with malignant tumor metastasis to the brain parenchyma confirmed by MRI scan.

      • Active infection with hepatitis B confirmed (HBsAg positive at Screening. But, in case of HBcAb IgG positive, the patient can be enrolled if he/she takes prophylactic anti-viral agent.)

        • Active infection with hepatitis C confirmed (HCV Ab tested positive at Screening. But, if screened negative for HCV RNA, the patient can be enrolled.) ④ Known human immunodeficiency virus (HIV) positive ⑤ Active neurological auto-immune or inflammatory disorder (e.g., Guillain Barre syndrome, amyotrophic lateral sclerosis) ⑥ Ventricular tachycardia and atrial fibrillation with rapid ventricular response not controlled (i.e., relapsed or symptomatic) with pharmacological treatment within three months prior to Screening
  3. Showing rapid progression of study disease as per Investigator's discretion
  4. Had major surgery requiring general anesthesia or mechanical ventilation within four weeks prior to Screening (for video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery, within two weeks prior to Screening)
  5. Severe infection requiring anti-bacterial, anti-fungal or anti-viral medication or uncontrolled active infection at Screening
  6. Use of other investigational medicinal products/devices within 4 weeks prior to Screening
  7. Pregnant or lactating women
  8. Hypersensitivity reaction to the ingredients of the Investigational Product

Other protocol-related inclusion/exclusion may apply.

Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (estimated)

Study arms

  • Experimental
    CRC01

    A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CRC01.

    Biological: CRC01 · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • BiologicalCRC01

    Cohort A :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg. Cohort B :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 1.5 x 10\^6 anti-CD19 CAR T cells/kg.

  • Administered according to package insert

  • Administered according to package insert

06

What researchers measure

Primary outcomes

  1. Phase 1 Study: Maximum Tolerated Dose (MTD) which will be the Recommended Phase 2 Dose (RP2D)

    Time frame: 28 days

  2. Phase 2 Pivotal Study: Cohort A : Overall Response Rate (ORR) Cohort B : Overall Complete Remission Rate (OCR)

    Cohort A : ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the Lugano Criteria for Response Assessment (2014). Cohort B : OCR is defined as the incidence of either a complete Remission (CR) or a Complete Remission with incomplete hematologic recovery (CRi) per the ALL Response Criteria.

    Time frame: 5 years

Secondary outcomes

  1. Time to response (TTR)

    Time frame: 5 years

  2. Duration of overall response (DOR)

    Time frame: 5 years

  3. Event free survival (EFS)

    Time frame: 5 years

  4. Progression free survival (PFS)

    Time frame: 5 years

  5. Overall survival (OS)

    Time frame: 5 years

  6. Incidence and severity of adverse events (AEs)

    Time frame: 5 years

  7. Incidence of immunogenicity to CRC01

    Time frame: 5 years

  8. Number of participants with presence of exposure to replication-competent lentivirus (RCL) as Assessed by quantitative polymerase chain reaction (qPCR)

    Time frame: 5 years

  9. Incidence of secondary malignancy

    Time frame: 5 years

  10. Peak concentration (Cmax) of CRC01 transduced cells into target tissues

    Time frame: 5 years

  11. Area under the concentration versus time curve (AUC) of CRC01 transduced cells into target tissues

    Time frame: 5 years

  12. Time to maximum observed concentration (Tmax) of CRC01 transduced cells into target tissues

    Time frame: 5 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Kim WS, Kim SJ, Yoon DH, Cho H, Yoon SE, Yang DH, Shin HJ, Eom HS, Lee E, Byun JM, Koh Y, Lee H, Jung J, Yoon SS, Song GY, Kim DY, Hong J, Park Y, Han S, Cho SH. Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01). Blood. 2026 Jun 12:blood.2025032636. doi: 10.1182/blood.2025032636. Online ahead of print. PubMed 42284198 ↗
  • Lee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Hupperetz C, Ma JSY, Wang X, Singer O, Kim WS, Kim SJ, Koh Y, Jung I, Kim CH. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther. 2022 Feb 2;30(2):579-592. doi: 10.1016/j.ymthe.2021.10.004. Epub 2021 Oct 8. PubMed 34628052 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Aug 2030, 113 months after the start.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's planned 113 months is above that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2021
First posted
Apr 8, 2021
StartActual
Mar 2, 2021
Primary completionEst.
Aug 15, 2030
CompletionEst.
Sep 26, 2030
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04836507
Lead sponsor
Curocell Inc.
Responsible party
Sponsor
First posted
Apr 8, 2021
Start date
Mar 2, 2021
Primary completion
Aug 15, 2030 (estimated)
Completion
Sep 26, 2030 (estimated)
Last update
Jul 1, 2026

Study contacts

Bom-I Kwon, BSc
Contact
bikwon@curocellbtx.com
+82428633698
Gunsoo Kim, MSc
Contact
gskim@curocellbtx.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion